BaeJC, ChoNH, SuhS, et al.: Cardiovascular disease incidence, mortality and case fatality related to diabetes and metabolic syndrome: a community-based prospective study (Ansung-Ansan cohort 2001–12). J Diabetes, 2014November18 [Epub ahead of print]. doi: 10.1111/1753-0407.12248.
2.
BrownRE, RiddellMC, MacphersonAK, et al.: All-cause and cardiovascular mortality risk in U.S. adults with and without type 2 diabetes: influence of physical activity, pharmacological treatment and glycemic control. J Diabetes Complications, 2014; 28:311–315.
3.
Cea SorianoL, JohanssonS, StefanssonB, et al.: Cardiovascular events and all-cause mortality in a cohort of 57,946 patients with type 2 diabetes: associations with renal function and cardiovascular risk factors. Cardiovasc Diabetol, 2015; 14:38.
4.
WilsonPW, D'AgostinoRB, LevyD, et al.: Prediction of coronary heart disease using risk factor categories. Circulation, 1998; 97:1837–1847.
5.
UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet, 1998; 352:837–853.
6.
StevensRJ, KothariV, AdlerAI, et al.: The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56). Clin Sci (Lond), 2001; 101:671–679.
7.
ZhouH, IsamanDJ, MessingerS, et al.: A computer simulation model of diabetes progression, quality of life, and cost. Diabetes Care, 2005; 28:2856–2863.
8.
KleinR, KleinBE, MossSE, et al.: The Wisconsin Epidemiologic study of diabetic retinopathy. III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years. Arch Ophthalmol, 1984; 102:527–532.
9.
LindM, Garcia-RodriguezLA, BoothGL, et al.: Mortality trends in patients with and without diabetes in Ontario, Canada and the UK from 1996 to 2009: a population-based study. Diabetologia, 2013; 56:2601–2608.
10.
GreggEW, LiY, WangJ, et al.: Changes in diabetes-related complications in the United States, 1990–2010. N Engl J Med, 2014; 370:1514–1523.
11.
HolzmannMJ, RathsmanB, EliassonB, et al.: Long-term prognosis in patients with type 1 and 2 diabetes mellitus after coronary artery bypass grafting. J Am Coll Cardiol, 2015; 65:1644–1652.
12.
ChoiSS, MehranR: Revascularization strategies in patients with Type 2 diabetes mellitus. Expert Rev Cardiovasc Ther, 2013; 11:1337–1347.
13.
MagnusonEA, FarkouhME, FusterV, et al.: Cost-effectiveness of percutaneous coronary intervention with drug eluting stents versus bypass surgery for patients with diabetes mellitus and multivessel coronary artery disease: results from the FREEDOM trial. Circulation, 2013; 127:820–831.
14.
SilvainJ, VignalouJB, BarthelemyO, et al.: Coronary revascularization in the diabetic patient. Circulation, 2014; 130:918–922.
15.
DoggrellSA: Percutaneous coronary intervention with drug-eluting stents or coronary artery bypass surgery in subjects with type 2 diabetes. Expert Opin Pharmacother, 2013; 14:1269–1273.
16.
HeeL, MussapCJ, YangL, et al.: Outcomes of coronary revascularization (percutaneous or bypass) in patients with diabetes mellitus and multivessel coronary disease. Am J Cardiol, 2012; 110:643–648.
17.
KamaleshM, SharpTG, TangXC, et al.: Percutaneous coronary intervention versus coronary bypass surgery in United States veterans with diabetes. J Am Coll Cardiol, 2013; 61:808–816.
18.
ChangSH, WuLS, LeeCH, et al.: Simvastatin-ezetimibe combination therapy is associated with a lower rate of major adverse cardiac events in type 2 diabetics than high potency statins alone: a population-based dynamic cohort study. Int J Cardiol, 2015; 190:20–25.
19.
Soedamah-MuthuSS, LivingstoneSJ, Charlton-MenysV, et al.: Effect of atorvastatin on C-reactive protein and benefits for cardiovascular disease in patients with type 2 diabetes: analyses from the Collaborative Atorvastatin Diabetes Trial. Diabetologia, 2015; 58:1494–1502.
20.
ThulesiusH: High LDL cholesterol and statin use were independently associated with lower eight-year mortality in a cohort free from terminal illness, cardiovascular disease, and diabetes at baseline. Scand J Prim Health Care, 2014; 32:1–2.
21.
HaoG, WangZ, GuoR, et al: Effects of ACEI/ARB in hypertensive patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled studies. BMC Cardiovasc Disord, 2014; 14:148.
22.
ZoungasS, ChalmersJ, NealB, et al.: Follow-up of blood-pressure lowering and glucose control in type 2 diabetes. N Engl J Med, 2014; 371:1392–1406.
23.
YeW, BrandleM, BrownMB, HermanWH: The Michigan Model for coronary heart disease in type 2 diabetes: development and validation. Diabetes Technol Ther, 2015; 17:701–711.
24.
KahnSE, HaffnerSM, HeiseMA, et al.: Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med, 2006; 355:2427–2443.
25.
GersteinHC, MillerME, ByingtonRP, et al.: Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med, 2008; 358:2545–2559.
26.
DuckworthW, AbrairaC, MoritzT, et al.: Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med, 2009; 360:129–139.
27.
PatelA, MacMahonS, ChalmersJ, et al.: Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet, 2007; 370:829–840.
28.
GriffinSJ, Borch-JohnsenK, DaviesMJ, et al.: Effect of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with type 2 diabetes detected by screening (ADDITION-Europe): a cluster-randomised trial. Lancet, 2011; 378:156–167.
29.
DabeleaD, Mayer-DavisEJ, SaydahS, et al.: Prevalence of type 1 and type 2 diabetes among children and adolescents from 2001 to 2009. JAMA, 2014; 311:1778–1786.
30.
TryggestadJB, WilliSM: Complications and comorbidities of T2DM in adolescents: findings from the TODAY clinical trial. J Diabetes Complications, 2015; 29:307–312.
31.
NarasimhanS, WeinstockRS: Youth-onset type 2 diabetes mellitus: lessons learned from the TODAY study. Mayo Clin Proc, 2014; 89:806–816.
